MENU
+Compare
AKBA
Stock ticker: NASDAQ
AS OF
Oct 14 closing price
Price
$2.79
Change
+$0.01 (+0.36%)
Capitalization
739.75M

AKBA Akebia Therapeutics Forecast, Technical & Fundamental Analysis

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company... Show more

Industry: #Biotechnology
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AKBA with price predictions
Oct 14, 2025

AKBA in +1.46% Uptrend, rising for three consecutive days on October 14, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AKBA advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 03, 2025. You may want to consider a long position or call options on AKBA as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AKBA just turned positive on October 02, 2025. Looking at past instances where AKBA's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where AKBA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AKBA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AKBA broke above its upper Bollinger Band on October 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AKBA entered a downward trend on October 13, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AKBA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (25.253) is normal, around the industry mean (17.643). P/E Ratio (0.000) is within average values for comparable stocks, (72.868). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.089). AKBA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (3.214) is also within normal values, averaging (48.567).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AKBA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AKBA is expected to report earnings to fall ∞% to -3 cents per share on November 06

Akebia Therapeutics AKBA Stock Earnings Reports
Q3'25
Est.
$-0.04
Q2'25
Beat
by $0.02
Q1'25
Beat
by $0.08
Q4'24
Missed
by $0.03
Q3'24
Missed
by $0.04
The last earnings report on August 07 showed earnings per share of 0 cents, beating the estimate of -1 cents. With 1.65M shares outstanding, the current market capitalization sits at 739.75M.
A.I. Advisor
published General Information

General Information

a developer of drugs for the treatment of anemia and vascular diseases

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Biotechnology
Address
245 First Street
Phone
+1 617 871-2098
Employees
167
Web
https://www.akebia.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IJMIX14.21N/A
N/A
VY® JPMorgan Mid Cap Value I
AEIYX8.98N/A
N/A
American Century Equity Income Y
FAPJX13.71N/A
N/A
Fidelity Advisor Healthy Future A
ILLLX32.19N/A
N/A
Transamerica Capital Growth C
MXXIX62.50N/A
N/A
Marsico Midcap Growth Focus Fund

AKBA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with XERS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+0.36%
XERS - AKBA
39%
Loosely correlated
+2.26%
IPSC - AKBA
38%
Loosely correlated
+1.84%
SYRE - AKBA
37%
Loosely correlated
+11.02%
FENC - AKBA
36%
Loosely correlated
-2.18%
RXRX - AKBA
36%
Loosely correlated
+6.51%
More

Groups containing AKBA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
+0.36%
Pharmaceuticals: Generic
industry (221 stocks)
29%
Poorly correlated
+1.43%
Pharmaceuticals
industry (385 stocks)
24%
Poorly correlated
+0.70%